PRESS RELEASE: Ground-breaking ALS start-up accepted into the Creation House program ofBioInnovation Institute (BII), securing funding of EUR 1.3 million Copenhagen, Denmark – September 22, 2020 The Bioinnovation Institute (BII) have accepted biotech start-up 2N Pharma into its Creation House program awarding the start-up EUR 1.3 million to develop its first in class treatment for the neurodegenerative disease ALS (amyotrophic […]
Meet us in Stockholm at the LSX Nordic Congress on 28-29 August 2019 at Nasdaq. We are very happy to meet with potential collaborators and investors, although we will be selective with the number of CROs we meet. Please do not hesitate to send a meeting invitation through the partnering system or contact us directly […]
2N Pharma AB was incorporated in Sweden today to build on a decade of John Nieland’s research in neurological disorders. This marks the formal beginning of the process to take potential therapies from preclinical results to humans. With an experienced management team that has done it before, we are looking forward to the challenges ahead.
2N Pharma was founded today by the experienced management team behind the clinical stage biotech company 2A Pharma AB. There is a long road ahead but we are excited to start the process of developing new treatments for serious neurological disorders.